单次分割肺SBRT治疗不可手术早期肺癌的十年经验
该研究回顾性分析了十年间采用单次分割立体定向体部放疗(SF-SBRT)治疗不可手术外周型早期肺癌的229例患者,剂量为34 Gy或30 Gy。中位总生存44.1个月,2年局部、淋巴结和远处失败率分别为7.3%、9.4%和12.2%,仅2例(0.9%)出现3级毒性,无4/5级毒性。两种剂量结局无显著差异,结果与两项随机试验相当,支持该方案常规应用。
要点
- 单次分割SBRT(34 Gy或30 Gy)治疗不可手术早期肺癌,2年局部失败率仅7.3%。
- 3级毒性发生率0.9%,无4/5级毒性,1-2级肺炎和胸壁毒性分别为7%和12.7%。
- 中位总生存44.1个月,两种剂量(34 Gy与30 Gy)结局无显著差异。
核心结论
- 单次分割肺SBRT治疗不可手术外周型早期肺癌的结局与两项随机试验相当,支持在常规实践中使用该方案。
- 在缺乏3期试验的情况下,本研究应鼓励对不可手术肿瘤增加使用SF-SBRT。
研究设计与样本
- 经机构审查委员会批准的前瞻性肺SBRT数据登记库回顾性分析,纳入至2019年12月底接受SF-SBRT且至少随访6个月的患者。
- 共229例患者符合标准,剂量为34 Gy或30 Gy。
主要发现
- 中位年龄74.6岁(范围47-94),女性占55%,中位Karnofsky体能状态80(范围50-100)。
- 肿瘤中位直径1.6 cm(范围0.7-4.1),中位PET SUVmax 6.1(范围0.8-24.3),63.6%患者接受活检。
- SF-SBRT剂量34 Gy占72.1%,30 Gy占27.9%,两组患者和肿瘤特征均衡。
- 30 Gy和34 Gy组总体中位随访时间分别为36.7和17.2个月(P < .0001)。
- 分析时55.9%患者存活,2例(0.9%)出现3级毒性,无4/5级毒性;1-2级肺炎和胸壁毒性分别见于7%和12.7%患者。
关键数值与推荐
- SF-SBRT剂量为34 Gy或30 Gy单次照射。
- 2年局部失败率7.3%,淋巴结失败率9.4%,远处失败率12.2%。
- 3级毒性发生率0.9%,无4/5级毒性。
临床怎么用
- 对于不可手术的外周型早期肺癌,可考虑单次分割SBRT(34 Gy或30 Gy)作为治疗选择。
- 治疗前应评估患者体能状态和肿瘤特征,本研究纳入中位KPS 80、中位肿瘤直径1.6 cm的患者。
局限性
- 本研究为单机构回顾性登记分析,非随机对照试验。
- 30 Gy和34 Gy组随访时间差异显著(P < .0001),可能影响结局比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To review 10 years of using single-fraction lung stereotactic body radiation therapy (SF-SBRT) for medically inoperable peripheral early-stage lung cancer. METHODS AND MATERIALS: An institutional review board-approved prospective lung SBRT data registry was surveyed until the end of December 2019 for all patients receiving SF-SBRT with minimum 6-month follow-up. Doses used were either 34 Gy or 30 Gy. Outcomes of interest included rates of local failure and overall survival (OS), as well as treatment-related toxicity graded per Common Terminology Criteria for Adverse Events version 3.0. RESULTS: A total of 229 patients met the study criteria. Patient characteristics included female sex (55%); median age, 74.6 years (range, 47-94); and median Karnofsky Performance Status 80 (range, 50-100). Tumor characteristics included median diameter, 1.6 cm (range, 0.7-4.1); median positron emission tomography standardized uptake value maximum 6.1 (range, 0.8-24.3); and 63.6% of patients biopsied. SF-SBRT dose was 34 Gy in 72.1% cases and 30 Gy in 27.9%, with patient and tumor characteristics balanced between cohorts. Overall median follow-up times for 30 Gy and 34 Gy were 36.7 and 17.2 months, respectively (P < .0001). At analysis, 55.9% patients were alive. Two (0.9%) patients developed grade 3 toxicities, and none had grade 4/5 toxicities. Grades 1 to 2 pneumonitis and chest wall toxicity were seen in 7% and 12.7% patients, respectively. Median overall survival was 44.1 months. Rates of 2-year local, nodal, and distant failure were 7.3%, 9.4%, and 12.2%, respectively. There were no significant differences in outcomes by dose. CONCLUSIONS: This is the largest institutional series to date reporting on SF-SBRT outcomes for medically inoperable peripheral early-stage lung cancer and the first to report on a decade's experience in implementing this schedule. Outcomes from this analysis are comparable to published results from 2 randomized trials and validate the use of this schedule in routine practice. In the absence of phase 3 trials, this study should encourage increased use of SF-SBRT for inoperable tumors.
引用
- Videtic GMM, Reddy CA, Woody NM, et al. Ten-Year Experience in Implementing Single-Fraction Lung SBRT for Medically Inoperable Early-Stage Lung Cancer. Int J Radiat Oncol Biol Phys. 2021. PMID: 34048817. doi:10.1016/j.ijrobp.2021.05.116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。